Probiota Asia 2017

Multi-strain versus single strain probiotics: More doesn’t necessarily mean better outcomes

By Gary Scattergood

- Last updated on GMT

Dr McFarland referenced published studies to compare clinical efficacy of single-strain versus multi-strain mixtures. ©iStock
Dr McFarland referenced published studies to compare clinical efficacy of single-strain versus multi-strain mixtures. ©iStock
More research is needed to assess the efficacy of multi-strain probiotic treatments, because current data shows that adding more strains doesn’t always lead to better outcomes for all illnesses.

That’s the view of international expert Dr Lynne McFarland, from the University of Seattle, who delivered a keynote address at our Probiota Asia summit in Singapore.

Dr McFarland, who has over 150 peer-reviews articles to her name, said there were pros and cons when considering if single or multi-strain options were preferable.

While the former are not subject to any other strain interference, have inherent stability, and come with clearly defined risks / drug interactions, the latter could benefit from more mechanisms of action and synergies, although it is harder to define risks and interactions.

During her presentation, she referenced published studies to compare clinical efficacy of single-strain versus multi-strain mixtures.

With regard to the prevention of antibiotic-associated diarrhoea, she said the single strain S. boulardii ​effectively prevents the illness in both paediatric and adult patients.

However, ​some mixtures (L. rhamnosus ​R11 and  L. helveticus ​R52) were found to be are more effective in preventing the illness, but only in children and not adults.

She added that several other single strains and mixtures lacked RCTs for both sub-populations.

Significant reductions

When it comes to eradicating Helicobacter pylori, Dr McFarland argued that both single and multi-strains showed significant benefits.

The single strain S. boulardii leads to a 0.66 day reduction ​of diarrhoea, while the ​two strain mixture L. rhamnosus ​R11 and L. helveticus ​R52 led to a 0.41 day reduction.

“These are both significan reductions, in my opinion,”​ she added.

However, mixes of two Lactobacilli strains, and S. boulardii ​and Bifido longum ​had only been assessed in one trial each, meaning no conclusions could be made.

Dr McFarland added: Surprisingly, adding more strains does not result in significantly higher efficacy in all diseases, but the benefits of multi-strain mixtures may include broader range of effects and more mechanisms of action because the synergy between strains in a mixture may be important.

“Building a rational mixture should be based on efficacy for single strains, then the effect of adding additional strains, but is clear that more research is needed.”

 

Related news

Show more

Related products

show more

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

Embrace Active Aging and ENJOY life!

Embrace Active Aging and ENJOY life!

Content provided by IFF | 05-Sep-2024 | Product Brochure

Live life to the fullest, regardless of age. Our science-backed formulas, packed with clinically studied probiotics and botanicals, empower you to age...

From Biofarma a clinically tested vaginal protection

From Biofarma a clinically tested vaginal protection

Content provided by Biofarma Group | 05-Sep-2024 | Product Brochure

Bacterial vaginosis is considered the most common cause of vaginal infection among pregnant and non-pregnant women. In this scenario, the oral intake of...

Related suppliers

Follow us

Products

View more

Webinars